RA
IRWD icon

Royce & Associates’s Ironwood Pharmaceuticals IRWD Stock Holding History

Royce & Associates’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.1K Buy
+18,553
New +$71.5K ﹤0.01% 740
2025
Q4 		– Sell
-300,619
Closed -$394K – 790
2025
Q3 		$394K Sell
300,619
-205,441
-41% -$213K ﹤0.01% 721
2025
Q2 		$363K Sell
506,060
-229,376
-31% -$180K ﹤0.01% 738
2025
Q1 		$1.08M Hold
735,436
– – 0.01% 664
2024
Q4 		$3.26M Buy
735,436
+72,502
+11% +$294K 0.03% 553
2024
Q3 		$2.73M Buy
662,934
+64,353
+11% +$346K 0.02% 580
2024
Q2 		$3.9M Buy
598,581
+7,577
+1% +$53.6K 0.04% 526
2024
Q1 		$5.15M Buy
591,004
+292,241
+98% +$3.55M 0.05% 488
2023
Q4 		$3.42M Buy
298,763
+14,013
+5% +$139K 0.03% 568
2023
Q3 		$2.74M Buy
284,750
+2,130
+0.8% +$20.9K 0.03% 604
2023
Q2 		$3.01M Sell
282,620
-1,603,627
-85% -$17.2M 0.03% 601
2023
Q1 		$19.8M Buy
1,886,247
+210,758
+13% +$2.36M 0.2% 136
2022
Q4 		$20.8M Sell
1,675,489
-2,722
-0.2% -$30.9K 0.22% 119
2022
Q3 		$17.4M Buy
1,678,211
+184,574
+12% +$2.09M 0.2% 134
2022
Q2 		$17.2M Buy
1,493,637
+332,791
+29% +$3.92M 0.18% 151
2022
Q1 		$14.6M Buy
1,160,846
+679,997
+141% +$7.8M 0.12% 241
2021
Q4 		$5.61M Buy
+480,849
New +$5.9M 0.04% 539
2020
Q3 		– Sell
-2,328
Closed -$24K – 1078
2020
Q2 		$24K Buy
2,328
+463
+25% +$4.74K ﹤0.01% 1108
2020
Q1 		$19K Buy
+1,865
New +$21.9K ﹤0.01% 1092

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Royce & Associates's IRWD Position: Q2 2026 in Review

Royce & Associates opened a new position in Ironwood Pharmaceuticals (IRWD) in Q2 2026: 18,553 shares worth $78.1K. The stake represents ﹤0.01% of the portfolio and ranks #740 among its holdings. This is a return to the name: Royce & Associates previously reported a position in IRWD as recently as Q3 2025.

Royce & Associates first reported a position in IRWD in Q1 2020 and has held it in 19 quarters since. The position peaked at $20.8M in Q4 2022. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Royce & Associates held 18,553 shares of Ironwood Pharmaceuticals worth $78.1K as of Q2 2026.
  • Ironwood Pharmaceuticals was a new Royce & Associates position in Q2 2026.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Royce & Associates's portfolio in Q2 2026, its #740 holding.
  • Royce & Associates first reported a position in Ironwood Pharmaceuticals in Q1 2020 and has held it in 19 quarters since.
  • Royce & Associates's Ironwood Pharmaceuticals position peaked at $20.8M in Q4 2022.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.